OppHub America Desk · · Source: yahoo-tickers-tape-movers
AbbVie vs. Johnson & Johnson: Healthcare Stock Comparison
Investors evaluating the healthcare sector may watch AbbVie for its focused growth in specific therapeutic areas, while Johnson & Johnson (JNJ) may appeal to those prioritizing diversification and stability within the sector.
Based on reporting from yahoo-tickers-tape-movers.
Investors weighing AbbVie Inc. (ABBV) against Johnson & Johnson (JNJ) must balance AbbVie's focused pharmaceutical growth potential against Johnson & Johnson's diversified medical conglomerate stability. AbbVie's reliance on three major distributors introduces a risk factor, while Johnson & Johnson's broad segments offer a more stable profile.
Market context for this story
As of: WeekendLoading quotes…
Informational only — not investment advice. Full markets →
$XLVHealth Care Select Sector
TradingView
Live chart & market data via TradingView · OppHub classroom · Delayed or exchange real-time per TradingView data agreements · Not investment advice
Educational TradingView chart — search any symbol in the widget. Confirm on /markets/XLV and related $ABBV, $JNJ. Not investment advice.
Related markets
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
**Implied Volatility / Movement:** Normal
Investors seeking healthcare exposure face a choice between AbbVie Inc. (ABBV) and Johnson & Johnson ($JNJ+WL). AbbVie, a biopharmaceutical company focused on immunology, oncology, and aesthetics, reported FY 2025 revenue of approximately $61.2 billion, with an 8.7% increase year-over-year and a net margin around 7%. A notable risk is its reliance on three primary distributors: McKesson Corp. (MCK), Cardinal Health Inc. (CAH), and Cencora Inc. (COR).
In contrast, Johnson & Johnson operates through its Innovative Medicine and MedTech segments. The Darzalex portfolio alone contributed about 15% of total 2025 revenues. For FY 2025, Johnson & Johnson reported revenue of $94.2 billion, up nearly 6% from the prior year, with a significant net income of $26.8 billion and a net margin of approximately 29%. The Innovative Medicine division constitutes 65% of its annual revenue.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
OppSHOP
Related to this story
Investors evaluating the healthcare sector may watch AbbVie for its focu
Shop related →
Investing books
Read the classics
Shop this pick →
Personal finance books
Run the household books
Shop this pick →
Trading notebooks
Write the thesis first
Shop this pick →
Monitor for charts
See every pane
Shop this pick →
Based on reporting from yahoo-tickers-tape-movers.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).